MEDICAL RESEARCH AND GENETIC RESOURCES MANAGEMENT: THE CASE OF TAXOL

A. Day Kelly and George Frisvold ()

Contemporary Economic Policy, 1993, vol. 11, issue 3, 1-11

Abstract: Commercial development of the anti‐cancer drug taxol has involved a complex set of interlocking research agreements. This paper explores the implications of such agreements and discusses diverse policy issues surrounding taxol development. Among these are forest management, species preservation, intellectual property rights, and the economics of biomedical research. Advances in genetic research increasingly have linked natural resource and technology policy issues. Institutional innovations in public/private research arrangements play a vital role in biotechnology development but are poorly understood. Policymakers need formal analyses of such agreements in order to evaluate complex research programs.

Date: 1993
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
https://doi.org/10.1111/j.1465-7287.1993.tb00385.x

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:coecpo:v:11:y:1993:i:3:p:1-11

Ordering information: This journal article can be ordered from
https://ordering.onl ... 5-7287&ref=1465-7287

Access Statistics for this article

Contemporary Economic Policy is currently edited by Brad R. Humphreys

More articles in Contemporary Economic Policy from Western Economic Association International Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().